Intuitive Has Its Eye on This Newcomer
In the following video, Motley Fool health care bureau chief Brenton Flynn continues his look at Intuitive Surgical's annual report. Specifically, he takes a look at one possible new competitive threat emerging on the company's radar. The company, called IMRIS, has its primary focus on intraoperative MRI technology, but is currently conducting clinical trials for a surgical platform targeting neurological conditions. Brenton tells investors whether this company is a concern and what other competitive threats Intuitive might be facing.
Are stories of Intuitive's demise greatly exaggerated?
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes a visible path to long-term growth persists. Will Intuitive capitalize, or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key new hits -- so be sure to claim your copy by clicking here now.
The article Intuitive Has Its Eye on This Newcomer originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Intuitive Surgical. The Motley Fool owns shares of Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.